BACKGROUND: Stability of circulating high-sensitivity C-reactive protein (hsCRP) concentrations has implications for its utility in assessing cardiovascular disease (CVD) risk. We sought to determine hsCRP reproducibility in an indigenous Australian cohort with a view to use hsCRP as a marker of future CVD in community-based risk-factor screenings. METHODS: Seventy people living in a community on the northern coast of Australia participated in 2 risk-factor screenings over a median (interquartile range) follow-up time of 829 (814-1001) days. hsCRP was measured by high-sensitivity nephelometry. RESULTS: Geometric mean hsCRP concentrations at baseline and follow-up were 4.5 and 5.1 mg/L, respectively (P = 0.220), and Pearson product-moment correlation was 0.775. The proportion of people at high CVD risk (hsCRP >3.0 mg/L) at baseline was 67.1% and remained consistently high (68.6%) at follow-up. Linear regression analysis for follow-up hsCRP as a function of baseline hsCRP, sex, and differences in total and regional body fatness showed that baseline hsCRP was the single predictor in the model, accounting for 63.9% of the total variance in follow-up hsCRP (P(model) < 0.001). Prevalence agreement (95% CI) between baseline and follow-up for the hsCRP >3.0 mg/L category was 84% (73%-92%) (P(McNemar) = not significant), and kappa coefficient was fair (0.64, compared with 0.31 for systolic blood pressure > or =140 mmHg and 0.43 for total cholesterol > or =5.5 mmol/L). CONCLUSIONS: hsCRP concentrations remained consistently reproducible over time across a wide concentration range in an Aboriginal cohort. Correlations between concentrations over time were better than for other traditional CVD risk factors. hsCRP concentration has potential as a marker of future CVD risk.
BACKGROUND: Stability of circulating high-sensitivity C-reactive protein (hsCRP) concentrations has implications for its utility in assessing cardiovascular disease (CVD) risk. We sought to determine hsCRP reproducibility in an indigenous Australian cohort with a view to use hsCRP as a marker of future CVD in community-based risk-factor screenings. METHODS: Seventy people living in a community on the northern coast of Australia participated in 2 risk-factor screenings over a median (interquartile range) follow-up time of 829 (814-1001) days. hsCRP was measured by high-sensitivity nephelometry. RESULTS: Geometric mean hsCRP concentrations at baseline and follow-up were 4.5 and 5.1 mg/L, respectively (P = 0.220), and Pearson product-moment correlation was 0.775. The proportion of people at high CVD risk (hsCRP >3.0 mg/L) at baseline was 67.1% and remained consistently high (68.6%) at follow-up. Linear regression analysis for follow-up hsCRP as a function of baseline hsCRP, sex, and differences in total and regional body fatness showed that baseline hsCRP was the single predictor in the model, accounting for 63.9% of the total variance in follow-up hsCRP (P(model) < 0.001). Prevalence agreement (95% CI) between baseline and follow-up for the hsCRP >3.0 mg/L category was 84% (73%-92%) (P(McNemar) = not significant), and kappa coefficient was fair (0.64, compared with 0.31 for systolic blood pressure > or =140 mmHg and 0.43 for total cholesterol > or =5.5 mmol/L). CONCLUSIONS: hsCRP concentrations remained consistently reproducible over time across a wide concentration range in an Aboriginal cohort. Correlations between concentrations over time were better than for other traditional CVD risk factors. hsCRP concentration has potential as a marker of future CVD risk.
Authors: Lauren C Peres; Adrianne R Mallen; Mary K Townsend; Elizabeth M Poole; Britton Trabert; Naomi E Allen; Alan A Arslan; Laure Dossus; Renée T Fortner; Inger T Gram; Patricia Hartge; Annika Idahl; Rudolf Kaaks; Marina Kvaskoff; Anthony M Magliocco; Melissa A Merritt; J Ramón Quirós; Anne Tjonneland; Antonia Trichopoulou; Rosario Tumino; Carla H van Gils; Kala Visvanathan; Nicolas Wentzensen; Anne Zeleniuch-Jacquotte; Shelley S Tworoger Journal: Cancer Res Date: 2019-08-28 Impact factor: 12.701
Authors: Elizabeth A Platz; Siobhan Sutcliffe; Angelo M De Marzo; Charles G Drake; Nader Rifai; Ann W Hsing; Ashraful Hoque; Marian L Neuhouser; Phyllis J Goodman; Alan R Kristal Journal: Cancer Causes Control Date: 2010-02-05 Impact factor: 2.506
Authors: Allison M Hodge; Louise Maple-Brown; Joan Cunningham; Jacqueline Boyle; Terry Dunbar; Tarun Weeramanthri; Jonathan Shaw; Kerin O'Dea Journal: BMC Public Health Date: 2010-11-15 Impact factor: 3.295